— Veligrotug labeling shows data for both the active and chronic forms of TED
June 29, 2026
• 2 min read
The FDA approved veligrotug (Lumvoa) for the treatment of thyroid eye disease (TED), regardless of disease activity or duration, Viridian Therapeutics announced on Friday.
Veligrotug is the first treatment with labeling for the active and chronic forms of the disease, with trials showing a statistically significant effect on both diplopia response and complete resolution in both, according to the drugmaker.
